Dimensional Fund Advisors LP Sells 868,264 Shares of AbbVie Inc. $ABBV

Dimensional Fund Advisors LP lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 10.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,411,238 shares of the company’s stock after selling 868,264 shares during the quarter. AbbVie makes up approximately 0.3% of Dimensional Fund Advisors LP’s holdings, making the stock its 29th biggest position. Dimensional Fund Advisors LP’s holdings in AbbVie were worth $1,611,690,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Scarborough Advisors LLC increased its stake in shares of AbbVie by 4.5% in the 1st quarter. Scarborough Advisors LLC now owns 1,812 shares of the company’s stock worth $394,000 after purchasing an additional 78 shares in the last quarter. Parallel Advisors LLC grew its holdings in AbbVie by 1.3% during the first quarter. Parallel Advisors LLC now owns 103,875 shares of the company’s stock valued at $22,592,000 after purchasing an additional 1,290 shares during the period. Resolute Wealth Strategies LLC grew its holdings in AbbVie by 1.5% during the first quarter. Resolute Wealth Strategies LLC now owns 5,025 shares of the company’s stock valued at $1,093,000 after purchasing an additional 72 shares during the period. AlphaCentric Advisors LLC increased its position in AbbVie by 19.0% in the first quarter. AlphaCentric Advisors LLC now owns 3,544 shares of the company’s stock worth $771,000 after buying an additional 565 shares in the last quarter. Finally, Pacific Wealth Strategies Group Inc. increased its position in AbbVie by 55.3% in the first quarter. Pacific Wealth Strategies Group Inc. now owns 3,051 shares of the company’s stock worth $664,000 after buying an additional 1,086 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ABBV shares. Wells Fargo & Company lifted their price objective on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, July 10th. Bank of America increased their target price on shares of AbbVie from $234.00 to $276.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Royal Bank Of Canada lifted their price target on shares of AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, July 10th. Canaccord Genuity Group upped their price target on shares of AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research report on Tuesday, June 23rd. Finally, UBS Group increased their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $267.67.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey® (trenibotulinumtoxinE), a new facial injectable for glabellar lines. The approval gives AbbVie a differentiated aesthetics product in all 30 EEA countries and could add another growth driver to offset Humira-related declines. Article Title
• Positive Sentiment: Investors are also focusing on AbbVie’s neuroscience franchise and other newer product catalysts, with analysts expecting solid Q2 growth and continued momentum from brands such as Vyalev, RINVOQ, and SKYRIZI ahead of earnings. Article Title
• Positive Sentiment: Brokerage sentiment remains constructive, with recent coverage showing a “Moderate Buy” consensus and multiple price-target increases in July, reinforcing confidence in AbbVie’s long-term pipeline and earnings outlook. Article Title
• Neutral Sentiment: Erste Group slightly lowered its FY2026 EPS estimate for AbbVie to $14.08 from $14.23, though the new estimate remains close to the consensus of $14.18 and is not a major deviation. Article Title

AbbVie Stock Up 0.0%

NYSE ABBV opened at $254.53 on Monday. AbbVie Inc. has a twelve month low of $184.63 and a twelve month high of $261.64. The business has a 50-day moving average price of $229.80 and a 200-day moving average price of $221.87. The firm has a market cap of $449.70 billion, a price-to-earnings ratio of 125.38, a price-to-earnings-growth ratio of 0.84 and a beta of 0.30.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the company earned $2.46 EPS. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. Research analysts expect that AbbVie Inc. will post 14.18 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.